EASL Studio - New therapeutic options and remaining challenges in PBC

 

Verena Keitel (Moderator), Carrie Frenette (Gilead representative), Tiago Nunes (Mirum representative), Dimitar Tonev (Ipsen representative), Phil Troke (GSK representative)

This EASL Studio is supported by CymaBay Therapeutics, Gilead, GSK, IPSEN, and Mirum.

Log in to post comments